Funapide
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
|
|
| Clinical data | |
| Routes of administration |
Oral, topical |
| Identifiers | |
| CAS Number | 1259933-16-8 |
| ATC code | None |
| PubChem | CID 49836093 |
| ChemSpider | 34500834 |
| Chemical data | |
| Formula | C22H14F3NO5 |
| Molar mass | 429.34547 g/mol |
|
|
|
Funapide (INN) (former developmental code names TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals in partnership with Teva Pharmaceutical Industries for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.[1][2][3][4] It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker.[1][2][4] Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.[1][3]
See also[edit]
References[edit]
- ^ a b c Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.
- ^ a b Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0.
- ^ a b Xenon Pharma. "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders".
- ^ a b Xenon Pharma (2012). "Teva and Xenon Announce Teva’s World Wide License of Xenon’s Pain Drug XEN402".
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
